Download PDF
Exp Clin Endocrinol Diabetes 2004; 112(2): 88-94
DOI: 10.1055/s-2004-815757
Article

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Effectiveness of a Disease Management Programme for Patients with Type 2 Diabetes Mellitus and Albuminuria in Primary Care - the PROSIT® Project (Proteinuria Screening and Intervention)

W. Steines1 , W. Piehlmeier2 , G. Schenkirsch2 , R. Renner1 , R. Landgraf2
  • 1Diabetes Centre, IIIrd Medical Department, Hospital Munich-Bogenhausen, Munich, Germany
  • 2Diabetes Centre, University Hospital, University of Munich, Munich, Germany
Further Information

Publication History

Received: July 26, 2002 First decision: October 16, 2002

Accepted: June 4, 2003

Publication Date:
19 March 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Aims

To evaluate the structured PROSIT® disease management programme for high-risk diabetic patients in primary care with respect to the cardio-vascular risk profile and mortality.

Subjects and Methods

Retrospectively 55 albuminuric Type 2 diabetic patients included into the PROSIT® programme from 1994 to 1999 (intervention group: age 66.6 ± 10.5 years, known duration of diabetes 8.9 ± 6.5 years) were compared with 58 albuminuric patients not participating in the PROSIT® programme (control group: age 68.5 ± 10.4 years, known duration of diabetes 8.5 ± 6.7 years). Within PROSIT® a structured multifactorial intervention programme was applied. The main characteristics of this intervention were strict follow-ups of the patient's risk profile every three months and the use of quality management methods (definition of target values, structured documentation, central data feedback with diagnostic and therapeutic recommendations based on European guidelines). The cardio-vascular risk profile, therapeutic intervention, and secondary diabetic complications were compared between both groups in 1994 and 1999.

Results

In the period from 1994 to 1999 the intervention group showed a significant improvement in the vascular risk profile, while the control group did not. In 1999 the mean arterial blood pressure was significantly lower compared to the control group (115 ± 13 mm Hg vs. 125 ± 16 mm Hg, p < 0.05). The HbA1c improved only in the intervention group and in 1999 it was significantly lower than in the control group (7.0 ± 1.3 % vs. 8.4 ± 1.8 %, p < 0.01). Moreover, the occurrence of clinical endpoints in the intervention group could be reduced: Both the mortalitly rate (14.5 % vs. 34.5 %, p < 0.05) and the rate of new myocardial infarctions (6 % vs. 20 %, p < 0.05) of the intervention group were significantly lower.

Conclusions

Participation of albuminuric Type 2 diabetic patients and their physicians in a structured intervention programme showed positive effects on the cardio-vascular risk profile and endpoints compared with a group of non-participating patients and physicians.

Key words

Type 2 diabetes mellitus - diabetic nephropathy - intervention - disease management - quality management

References

  • 1 Amos A F, McCarty D J, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010.  Diabet Med. 1997;  14 (Suppl 5) S1-85
    PubMedGoogle Scholar
  • 2 Borch-Johnsen K, Wenzel H, Viberti G C, Mogensen C E. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? (published erratum appears in BMJ 1993; 28: 307: 543) [see comments].  BMJ. 1993;  306 1722-1725
    PubMedGoogle Scholar
  • 3 DCCT . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [see comments].  N Engl J Med. 1993;  329 977-986
    Google Scholar
  • 4 Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen J S. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes.  BMJ. 1996;  312 871-874
    PubMedGoogle Scholar
  • 5 Detournay B, Fagnani F, Pribil C, Eschwege E. Medical resources consumption of type 2 diabetics in France in 1998.  Diabetes Metab. 2000;  26 225-231
    PubMedGoogle Scholar
  • 6 Gaede P, Vedel P, Parving H H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study [see comments].  Lancet. 1999;  353 617-622
    CrossrefPubMedGoogle Scholar
  • 37 Gaede P, Vedel P, Larsen N, Jensen G VH, Parving H H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
    Google Scholar
  • 7 Garg A. Dyslipoproteinemia and diabetes.  Endocrinol Metab Clin North Am. 1998;  27 613-615
    CrossrefPubMedGoogle Scholar
  • 8 Grimshaw J, Russel I. Achieving health gain through clinical guidelines: II: Ensuring guidelines change medical practice.  Quality in Health Care. 1994;  3 45-52
    PubMedGoogle Scholar
  • 9 Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn K H, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group [see comments].  Lancet. 1998;  351 1755-1762
    CrossrefPubMedGoogle Scholar
  • 10 Hasslacher C. Clinical significance of microalbuminuria and evaluation of the Micral-Test.  Clin Biochem. 1993;  26 283-287
    PubMedGoogle Scholar
  • 11 Jager A, Kostense P J, Ruhe H G, Heine R J, Nijpels G, Dekker J M, Bouter L M, Stehouwer C D. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study.  Arterioscler Thromb Vasc Biol. 1999;  19 617-624
    PubMedGoogle Scholar
  • 12 Jonsson B. The economic impact of diabetes.  Diabetes Care. 1998;  21 (Suppl 3) C7-10
    PubMedGoogle Scholar
  • 13 Kreisberg R A. Diabetic dyslipidemia.  Am J Cardiol. 1998;  82 67U-73U
    CrossrefPubMedGoogle Scholar
  • 14 Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes [see comments].  Circulation. 1993;  88 1421-1430
    CrossrefPubMedGoogle Scholar
  • 15 Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies.  Ann Intern Med. 1996;  124 127-130
    PubMedGoogle Scholar
  • 16 Lippert J, Ritz E, Schwarzbeck A, Schneider P. The rising tide of endstage renal failure from diabetic nephropathy type II - an epidemiological analysis [see comments].  Nephrol Dial Transplant. 1995;  10 462-467
    PubMedGoogle Scholar
  • 17 Luno J, Garcia de Vinuesa S, Gomez-Campdera F, Lorenzo I, Valderrabano F. Effects of antihypertensive therapy on progression of diabetic nephropathy.  Kidney Int Suppl. 1998;  68 S112-119
    PubMedGoogle Scholar
  • 18 Mathiesen E R, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study.  Diabet Med. 1995;  12 482-487
    PubMedGoogle Scholar
  • 19 Mogensen C E. Management of early nephropathy in diabetic patients.  Ann Rev Med. 1995;  46 79-93
    CrossrefPubMedGoogle Scholar
  • 20 Mogensen C E, Viberti G C, Peheim E, Kutter D, Hasslacher C, Hofmann W, Renner R, Bojestig M, Poulsen P L, Scott G, Thoma J, Kuefer J, Nilsson B, Gambke B, Mueller P, Steinbiss J, Willamowski K D. Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria [see comments].  Diabetes Care. 1997;  20 1642-1646
    PubMedGoogle Scholar
  • 21 Mogensen C E. Natural history of cardiovascular and renal disease in patients with type 2 diabetes: effect of therapeutic interventions and risk modification.  Am J Cardiol. 1998;  82 4R-8R
    CrossrefPubMedGoogle Scholar
  • 22 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study [see comments].  Diabetes Res Clin Pract. 1995;  28 103-117
    CrossrefPubMedGoogle Scholar
  • 23 Piehlmeier W, Renner R, Schramm W, Kimmerling T, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R. Screening of diabetic patients for microalbuminuria in primary care- The PROSIT-Project. Proteinuria Screening and Intervention.  Exp Clin Endocrinol Diabetes. 1999;  107 244-251
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Piehlmeier W, Renner R, Kimmerling T, Schramm W, Garbe S, Proetzsch R, Fahn J, Piwernetz K, Landgraf R. Evaluation of the Micral-Test S, a Qualitative Immunologic Patient Self-test for Microalbuminuria: the PROSIT Project.  Diabetic Medicine. 1998;  15 883-885
    CrossrefPubMedGoogle Scholar
  • 25 Poulsen P L, Ebbehoj E, Hansen K W, Mogensen C E. Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients.  Am J Hypertens. 1998;  11 1093-1099
    CrossrefPubMedGoogle Scholar
  • 26 Ritz E, Lippert J, Keller C. A rapid rise in the number of type-2 diabetics in kidney failure. Not just a problem of nephrologists (editorial).  Dtsch Med Wochenschr. 1996;  121 1247
    PubMedGoogle Scholar
  • 27 Ritz E, Rychl, Locatelli F, Halimi S. End-Stage Renal Failure in Type 2 Diabetes: A Medical Catastrophe of Worldwide Dimensions.  Am J Kidney Dis. 1999;  34 795-808
    PubMedGoogle Scholar
  • 28 Rychlik I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus.  Nephrol Dial Transplant. 1998;  13 (Suppl 8) 6-10
    PubMedGoogle Scholar
  • 29 Cooperative Research Group S HEP. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group [see comments].  JAMA. 1991;  265 3255-3264
    CrossrefPubMedGoogle Scholar
  • 30 Sheth J J. Diabetes, microalbuminuria and hypertension.  Clin Exp Hypertens. 1999;  21 61-68
    PubMedGoogle Scholar
  • 31 Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.  Diabetes Care. 2000;  23 (Suppl 2) B21-29
    PubMedGoogle Scholar
  • 32 Tatti P, Pahor M, Byington R P, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM [see comments].  Diabetes Care. 1998;  21 597-603
    CrossrefPubMedGoogle Scholar
  • 33 Thivolet C, Ayzac L, Simonet C, Rebattu B, Bernard P, Tourniaire J. Microalbuminuria and diabetic nephropathy. Detection and correlation with other degenerative complications.  Presse Med. 1990;  19 1075-1080
    PubMedGoogle Scholar
  • 34 UKPDS-Group. Intensive blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.  BMJ. 1998;  317 703-713
    PubMedGoogle Scholar
  • 35 UKPDS-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments].  Lancet. 1998 a;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 36 UKPDS-Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group (published erratum appears in Lancet 1998; 352: 1557) [see comments].  Lancet. 1998 b;  352 854-865
    CrossrefPubMedGoogle Scholar

W. Steines

IIIrd Medical Department, Hospital Munich-Bogenhausen

Englschalkinger Str. 77

81925 München

Germany

Phone: + 498992702503

Fax: + 49 89 51 60 21 03

Email: prosit@prosit.de

      >